A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

A drug widely available in Europe and Canada – but not the United States – dramatically eases one of the most disabling symptoms of Huntington’s disease, involuntary writhing movements known as chorea ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Please provide your email address to receive an email when new articles are posted on . Mean change from baseline in UHDRS TMC score was more significant in patients treated with valbenazine compared ...

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington’s disease, according to a recent international study led by UTHealth Houston researcher Erin Furr ...

The phase 3 KINECT-HD study included 128 adults 18 to 75 years of age who were diagnosed with chorea associated with HD. Positive topline data were announced from a phase 3 study evaluating the ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Neurocrine Biosciences today announced positive top-line data from its Phase 3 KINECT-HD study evaluating the efficacy, safety and tolerability of valbenazine, a selective vesicular monoamine ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...

Baseline clinical status was markedly different between Black and white patients with Huntington's disease, data from the Enroll-HD study showed. Across clinical measures, Black patients with ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...